Product Liability

Hair Dye Chemical (PPD) Cancer & Injury Litigation

Hair Dye Chemical (PPD) Cancer & Injury Litigation — Product Liability class action lawsuit

Case Overview

Paraphenylenediamine (PPD) is the primary oxidative dye agent found in most permanent hair coloring products sold by major brands including L'Oréal, Clairol, and Revlon. Epidemiological studies, including a prominent 2019 study from the National Institutes of Health (NIH) tracking over 46,000 women, found that regular use of permanent hair dye was associated with a 9% increased risk of breast cancer overall, rising to a 60% increased risk among Black women, as well as elevated rates of bladder cancer and non-Hodgkin's lymphoma. Plaintiffs allege the defendant companies were aware of these chemical risks for decades but concealed the dangers and failed to warn consumers.

Mass tort lawsuits have been filed across the country, with growing coordination in the Southern District of New York. Plaintiffs — predominantly women who used permanent hair dye regularly for many years — allege negligence, failure to warn, design defect, and fraudulent concealment under state product liability laws. The litigation is distinct from (though often compared with) the chemical hair relaxer cancer lawsuits. Defendants have aggressively challenged the science underlying the claims, and Daubert hearings on expert causation testimony are anticipated to be a pivotal battleground. The litigation is in its early stages, with discovery ongoing as of 2025.

Who May Qualify

Individuals, primarily women, who used permanent (oxidative) hair dye products containing PPD or similar chemicals on a regular basis (typically for 1+ years) and were subsequently diagnosed with bladder cancer, non-Hodgkin's lymphoma, breast cancer, or other cancers potentially linked to hair dye chemical exposure.

Frequently Asked Questions

Does hair dye cause cancer?

Several major epidemiological studies, including one from the National Institutes of Health, have found a statistical association between long-term use of permanent hair dye and increased risk of bladder cancer, non-Hodgkin's lymphoma, and breast cancer — particularly among Black women. The lawsuits allege manufacturers failed to warn consumers of these risks.

Which hair dye brands are included in the lawsuit?

Current lawsuits name major permanent hair color brands including L'Oréal (Féria, Excellence Crème), Clairol (Nice 'n Easy, Natural Instincts Permanent), and Revlon (ColorSilk). The lawsuits focus on products containing paraphenylenediamine (PPD), a chemical found in most permanent hair dyes.

How is the hair dye lawsuit different from the hair relaxer lawsuit?

The hair relaxer litigation focuses on chemical straighteners and their link to uterine and ovarian cancers, primarily affecting Black women. The hair dye litigation concerns oxidative dye chemicals like PPD found in permanent hair color products and their association with bladder cancer, lymphoma, and breast cancer. They are separate mass tort cases targeting different products and chemical compounds.

Related Cases

Social Media Addiction & Youth Mental Health School District MDL — Product Liability class action lawsuit

Social Media Addiction & Youth Mental Health School District MDL

Current
Product Liability
Hundreds of school districts and personal injury plaintiffs allege that Meta, Snap, TikTok, and YouTube deliberately designed their platforms to be addictive to children and teenagers, causing a nationwide youth mental health crisis resulting in anxiety, depression, self-harm, eating disorders, and suicide.
Ozempic / Mounjaro GI Injury (Gastroparesis & Bowel Obstruction) Products Liability MDL — Product Liability class action lawsuit

Ozempic / Mounjaro GI Injury (Gastroparesis & Bowel Obstruction) Products Liability MDL

Current
Product Liability
Patients who used GLP-1 receptor agonist drugs Ozempic (semaglutide) and Mounjaro (tirzepatide) for weight loss or diabetes management allege they suffered severe gastrointestinal injuries — including gastroparesis (stomach paralysis), bowel obstruction, and intestinal ileus — that were not adequately disclosed in the drugs' warnings.
Victoza (Liraglutide) Lawsuit: Vision Loss (NAION) Claims — Product Liability class action lawsuit

Victoza (Liraglutide) Lawsuit: Vision Loss (NAION) Claims

Current
Product Liability
Victoza (liraglutide) lawsuits claim that Novo Nordisk failed to warn patients about the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden vision loss. Users of the GLP-1 diabetes drug allege that the manufacturer did not adequately disclose the potential eye damage risks.